For research use only
| Cat No. | ABC-TC0239 |
| Product Type | Mouse Breast Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Mouse |
| Growth Conditions | 37 ℃, 5% CO2 |
| Product Code | Ehrlich-Lettre; Ehrlich Lettre; E-La; EAT; EAT strain E; Ehrlich ascites; Ehrlich |
Mouse carcinoma. Established from the explant of a 7 day old tumour from the parental Ehrlich-Lettre Ascites carcinoma.
Ehrlich-Lettre Ascites strain E cell line is an Ehrlich ascites tumor cell line originally isolated from mouse breast tissue of a female Mus musculus with malignant mammary neoplasm. This cell line exhibits epithelial-like morphology and demonstrates adherent growth properties in vitro culture conditions. Cytogenetic analysis confirms that these cells exhibit a diploid chromosome composition, defined by a consistent chromosomal number of 2n=40. This cell line demonstrates both tumorigenic potential and metastatic capability in appropriate model systems. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | Ehrlich-Lettre; Ehrlich Lettre; E-La; EAT; EAT strain E; Ehrlich ascites; Ehrlich |
| Species | Mouse |
| Cat.No | ABC-TC0239 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Mouse Breast Cancer Cell Lines |
Ehrlich-Lettre Ascites strain E cells function as a murine carcinoma model, specifically utilized to investigate fundamental tumor proliferation mechanisms and chemotherapy resistance pathways. They provide a robust platform enabling highly reproducible in vivo-mimetic drug efficacy screening procedures and detailed tumor-host interaction analyses. This integrated system further facilitates precise metastasis quantification within peritoneal dissemination models and comprehensive immunomodulator testing, crucially accelerating targeted therapeutic development initiatives for aggressive carcinomas.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).